CASE REPORT article
Front. Cardiovasc. Med.
Sec. General Cardiovascular Medicine
Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1512784
This article is part of the Research TopicCase Reports in General Cardiovascular Medicine: 2024View all 12 articles
Practice of Whole-Course Pharmaceutical Care: A Case in Hypertrophic Cardiomyopathy and A Review of Pharmacist Role
Provisionally accepted
- 1Department of Pharmacy, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China
- 2Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, China
- 3Department of Pharmacy, Deqing People's Hospital, Huzhou, China
- 4Department of Pharmacy, the People's Hospital of Pingyang Hospital, Wenzhou, China
- 5Department of Pharmacy, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Clinical pharmacists assessed clinicians in medication planning and health education management for a male patient diagnosed with hypertrophic cardiomyopathy (HCM).Therapeutically, diltiazem was changed to metoprolol for the purpose of further improving symptoms. The exon gene sequencing analysis of whole blood revealed the presence of a mutation and dominant inheritance of the pathogenic gene for HCM with the beta myosin heavy chain gene (MYH7, OMIM #160760). Furthermore, low-intensity exercise and screening for HCM genes in children are advisable accordingly. Additionally, we conducted an overview of current therapeutic approaches, emphasizing potential novel agents and non-pharmaceutical interventions for the effective management of HCM. This report, for the first time, not only updates HCM treatment practices but also highlights pharmacists' roles in long-term HCM management.
Keywords: Hypertrophic Cardiomyopathy, Treatment, Diltiazem, Metoprolol, pharmaceutical care
Received: 17 Oct 2024; Accepted: 20 Jun 2025.
Copyright: © 2025 Li, Zhang, Sun, Xu and Mao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yao-Yao Xu, Department of Pharmacy, the People's Hospital of Pingyang Hospital, Wenzhou, China
Kai-Li Mao, Department of Pharmacy, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.